CONMED CORPORATION Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
CONMED CORPORATION (CNMD) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 0 shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2026-02-17
- CONMED CORPORATION incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2024-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- CONMED CORPORATION incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2024-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- CONMED CORPORATION incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2024-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- CONMED CORPORATION incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2023-09-30 was 178.00K shares, a 295.56% increase year-over-year.
- CONMED CORPORATION incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2025 was 0.00 shares.
- CONMED CORPORATION incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2024 was 0.00 shares, a 100.00% decline from fiscal 2023.
- CONMED CORPORATION incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2023 was 142.00K shares.
- CONMED CORPORATION incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2022 was 0.00 shares, a 100.00% decline from fiscal 2021.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 0.00 shares 10-K · filed 2026-02-17 | |||||||
| 2024-12-31 | 0.00 shares 10-K · filed 2026-02-17 | |||||||
| 2024-09-30 | 0.00 shares 10-Q · filed 2024-10-31 | 0.00 shares 10-Q · filed 2024-10-31 | ||||||
| 2024-06-30 | 0.00 shares 10-Q · filed 2024-08-01 | 0.00 shares 10-Q · filed 2024-08-01 | ||||||
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-04-25 | |||||||
| 2023-12-31 | 142.00K shares 10-K · filed 2026-02-17 | |||||||
| 2023-09-30 | 178.00K shares 10-Q · filed 2024-10-31 | 152.00K shares 10-Q · filed 2024-10-31 | ||||||
| 2023-06-30 | 214.00K shares 10-Q · filed 2024-08-01 | 139.00K shares 10-Q · filed 2024-08-01 | ||||||
| 2023-03-31 | 64.00K shares 10-Q · filed 2024-04-25 | |||||||
| 2022-12-31 | 0.00 shares 10-K · filed 2025-02-18 | |||||||
| 2022-09-30 | 45.00K shares 10-Q · filed 2023-10-26 | 0.00 shares 10-Q · filed 2023-10-26 | ||||||
| 2022-06-30 | 0.00 shares 10-Q · filed 2023-07-27 | 0.00 shares 10-Q · filed 2023-07-27 | ||||||
| 2022-03-31 | 3.88M shares 10-Q · filed 2023-04-27 | |||||||
| 2021-12-31 | 1.27M shares 10-K · filed 2024-02-28 | 1.30M shares 10-K · filed 2022-02-22 | ||||||
| 2021-09-30 | 1.24M shares 10-Q · filed 2022-10-27 | 1.20M shares 10-Q · filed 2021-10-28 | 1.21M shares 10-Q · filed 2022-10-27 | 1.20M shares 10-Q · filed 2021-10-28 | ||||
| 2021-06-30 | 1.36M shares 10-Q · filed 2022-07-28 | 1.40M shares 10-Q · filed 2021-07-29 | 1.20M shares 10-Q · filed 2022-07-28 | 1.20M shares 10-Q · filed 2021-07-29 | ||||
| 2021-03-31 | 1.01M shares 10-Q · filed 2022-05-05 | 1.00M shares 10-Q · filed 2021-04-29 | ||||||
| 2020-12-31 | 200.00K shares 10-K · filed 2021-02-22 | 0.00 shares 10-K · filed 2023-02-21 | ||||||
| 2020-09-30 | 200.00K shares 10-K · filed 2021-02-22 | |||||||
| 2020-03-31 | 100.00K shares 10-Q · filed 2021-04-29 | |||||||
| 2019-12-31 | 600.00K shares 10-K · filed 2021-02-22 | |||||||
| 2019-09-30 | 200.00K shares 10-Q · filed 2020-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Neuraxis, INC (NRXS) | United States | $0.097B |